Recently in Weight Loss Category
PHARMACEUTICAL company Roche's plans to make its controversial weight loss drug Xenical a household name have been dealt a severe blow.
The National Drugs and Poisons Schedule Committee has decided to stop it advertising directly to the consumer.
Roche Products said it would not appeal against the decision to revoke its licence to advertise. The regulator found Xenical's marketing generated increased demand among consumers who might not need the drug.
By Dr. John Briffa
Some of you may remember that the Coca-Cola Corporation announced the forthcoming launch of its "weight loss" drink Enviga. Naturally, I felt compelled to blog about this on my own website, and included a calculation which revealed that (if what the Coca-Cola Corporation says is taken at face value) each kilogram of weight lost through the imbibing of the beverage would cost about $650 .
Well, finally the Coca-Cola Corporation have got Enviga onto shelves in America, and have done this by teaming up with the food company giant Nestlé. The behemoth formed by the unholy union of these two food companies goes by the name of Beverage Partners Worldwide (BPW). No doubt, with its promise of weight loss, BPW see Enviga as a ticket to further its quest for fat profits.
By Sally Squires, Washington Post Staff Writer
The Food and Drug Administration recently approved the first nonprescription drug for weight loss. Alli (pronounced AL-eye) is slated to hit shelves this year, according to its maker, GlaxoSmithKline (GSK). That move has been denounced by some who say it should not be made so readily available because of limited efficacy and safety concerns.
Before you even consider this drug, there are some facts you need to know and some questions to ponder:
Gosh, how much weight can I lose with this new drug? First, the drug isn't new. It contains orlistat, a weight-loss medication that has been sold by prescription as Xenical for nine years worldwide and since 1999 in the United States. There have been about 100 studies of the drug involving some 30,000 people. The results suggest that users can shed as much as 50 percent more weight than they would by diet alone.
WASHINGTON - As more Americans struggle with growing waistlines, U.S. health officials Wednesday set out their own tips for drugmakers seeking to develop products for people trying to shed pounds.
The Food and Drug Administration’s draft guidelines — more than 10 years in the making — aim to help companies develop and test new drugs and devices for treating obesity.
About a third of U.S. adults, or more than 60 million people, are obese and another third are overweight, government statistics show. Nearly a fifth of U.S. children weigh too much.
DIETS and exercise may not be the future for weight loss.
A pacemaker-like device, which blocks hunger nerves, has been successfully trialled at Adelaide's Flinders Medical Centre, with stunning results.
The first person to be implanted with the device lost 20 kilograms in a year without changing her dietary habits or exercise regime.
The Adelaide medical centre was one of three in the world to trial the new device, developed by EnteroMedics Inc.
Flinders' Professor of Digestive Surgery James Toouli (Toouli) said the instrument was placed under the abdominal skin and powered by parts worn outside the body.
The drug, called alli (orlistat), is designed to be used only in tandem with a reduced-calorie, low-fat diet by overweight adults 18 and older. According to manufacturer GlaxoSmithKline, the drug helps people lose 50 percent more weight than dieting alone, should cost consumers $12 to $25 a week and is expected to be available by this summer.
"This is the only FDA-approved, over-the-counter weight loss drug product," Dr. Charles J. Ganley, the FDA's director of the Division of Over-The-Counter Drug Products, said during a teleconference. "There are some products, primarily dietary supplements, that make weight-loss claims and those are not FDA-approved, although they are permitted to make these claims."
And yesterday, Luna filed suit in Los Angeles County Superior Court, alleging the advertising is "false or misleading."
Website TMZ.com, which obtained the lawsuit against Smith and Trimspa, points out that the plaintiff is possibly a minor, as the suit was filed by her mother, Myra Luna.
A single protein in brain cells may act as a linchpin in the body's weight-regulating system, playing a key role in the flurry of signals that govern fat storage, sugar use, energy balance and weight, University of Michigan Medical School researchers report.
And although it's far too early to say how this protein could be useful in new strategies to fight the world?s epidemic of obesity, the finding gives scientists an important system to target in future research and the development of anti-obesity medications.
In the February issue of the Journal of Clinical Investigation, U-M researcher Liangyou Rui, Ph.D. and his team report their findings on a protein called SH2B1, and specifically on its activity in brain cells.